How has this agent changed the treatment landscape following this initial approval?

Yeah, the treatment landscape itself is incredibly dynamic.

When this product was conceived by a small startup company in Gametacel in, say, 2011, 2012, the landscape for what we consider as alternative donor transplantation, meaning allogeneic transplantation using donors other than adult match donors was wide open, and there was a great clinical need for such donors.

But over the last 10 to 15 years, that's changed quite a bit, and there are many options for patients who don't have a match.

And Omidubacill with its FDA approval is just one of a number of these options.

Umbilical cord blood transplantation has been in practice for over 40 years, and it continues to be a very important graft source for children.

But for adults, it was always a bit of a struggle and difficult.

And as we sort of begin to wrap up here, what do you ultimately hope your colleagues and listeners take away from this discussion, considering everything we talked about from the prophylaxis to the approvals for Amadupacil?